Inbrain Neuroelectronics, a CataloniaBio & HealthTech member, announces a collaboration with Merck to co-develop the next generation of graphene bioelectronic vagus nerve therapies targeting severe chronic diseases in Merck’s therapeutic areas.
The collaboration will be carried out through Inbrain’s subsidiary Innervia Bioelectronics.
Inbrain is one of the most advanced and promising neurotechnology companies in the world (created at the crossroads of medical technology, deeptech and digital health). Recently, digital media outlet Sifted.eu (Financial Times) ranked it ahead of Elon Musk’s company Neuralink.
“Bioelectronic devices have the capability to directly communicate with the nervous system. Recording nerve signals and combining them with other accessible physiological datasets will lead to a better understanding of disease conditions and enable personalized treatment regimens,” said Robert Spoelgen, head of Bioelectronics of the Merck Innovation Centre. “We are convinced that bioelectronic devices will play a significant role in the future therapeutic landscape.”
Inbrain's main investors are Alta Life Sciences and Asabys based in Barcelona.
Photo: Cristina Aguilar, co-founder and CEO of Inbrain Neuroelectrics.
You may also be interested in:
Inbrain Neuroelectronics completes €14.3-million Series A funding round
Comments